AB&B BIO-TECH-B (02627) announced that its H-shares have been selected and will be included as a constituent stock of the Hang Seng Composite Index, effective from March 9, 2026. The Hang Seng Composite Index serves as a comprehensive H-share benchmark, covering companies listed on the Main Board of the Hong Kong Exchange that collectively represent the top 95% of cumulative market capitalization. It is widely used by index funds, mutual funds, and performance evaluation systems. The Board of Directors believes that the company's inclusion in the Hang Seng Composite Index reflects capital market recognition of its business performance and growth prospects. The Board is confident that this inclusion will help broaden the company's shareholder base, enhance the trading liquidity of its H-shares, and further strengthen its reputation and brand visibility.
Comments